nach oben

Der Nervenarzt

Erschienen in:

20.09.2017 | Enzephalitis | CME

Update Anti-N-Methyl-D-Aspartat-Rezeptor-Enzephalitis

verfasst von: S. Kovac, J. Alferink, D. Ahmetspahic, V. Arolt, PD Dr. N. Melzer

Erschienen in: Der Nervenarzt | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Autoimmunenzephalitiden sind eine Gruppe autoimmun-entzündlicher Erkrankungen der grauen und weißen Substanz des zentralen Nervensystems. Die Enzephalitis mit Autoantikörpern gegen den N‑Methyl-D-Aspartat-Rezeptor (NMDA-R) ist die häufigste autoimmune Enzephalitis. Sie manifestiert sich meist mit einer Abfolge typischer psychiatrischer und neurologischer Symptome, und ihre Therapie erfordert damit eine enge interdisziplinäre Zusammenarbeit. Der Beitrag gibt eine aktualisierte Übersicht über den derzeitigen Kenntnisstand zur Diagnostik, Pathogenese und Therapie der Anti-NMDA-R-Enzephalitis aus psychiatrischer und neurologischer Perspektive.

Lancaster E, Martinez-Hernandez E, Dalmau J (2011) Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77:179–189CrossRefPubMedPubMedCentral

Dalmau J, Tüzün E, Wu H et al (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36CrossRefPubMedPubMedCentral

Irani SR, Vincent A (2012) The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr 70:300–304CrossRefPubMed

Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (2012) The frequency of autoimmune N‑methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 54:899–904CrossRefPubMedPubMedCentral

Prüß H, Dalmau J, Arolt V, Wandinger K‑P (2010) Anti-NMDA-Rezeptor-Enzephalitis. Nervenarzt 81:396–408CrossRefPubMed

Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165CrossRefPubMedPubMedCentral

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10:63–74CrossRefPubMedPubMedCentral

Irani SR, Bera K, Waters P et al (2010) N‑methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133:1655–1667CrossRefPubMedPubMedCentral

Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J (2013) The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 28:543–547CrossRefPubMed

10.

Leypoldt F, Armangue T, Dalmau J (2015) Autoimmune encephalopathies. Ann N Y Acad Sci 1338:94–114CrossRefPubMed

11.

Hammer C, Stepniak B, Schneider A et al (2014) Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 19:1143–1149CrossRefPubMed

12.

Kirkpatrick MP, Clarke CD, Sonmezturk HH, Abou-Khalil B (2011) Rhythmic delta activity represents a form of nonconvulsive status epilepticus in anti-NMDA receptor antibody encephalitis. Epilepsy Behav 20:392–394CrossRefPubMed

13.

Sands TT, Nash K, Tong S, Sullivan J (2015) Focal seizures in children with anti-NMDA receptor antibody encephalitis. Epilepsy Res 112:31–36CrossRefPubMed

14.

Viaccoz A, Desestret V, Ducray F et al (2014) Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology 82:556–563CrossRefPubMed

15.

Gascon GG, al-Jarallah AA, Okamoto E, al Ahdal M, Kessie G, Frayha H (1993) Chorea as a presentation of herpes simplex encephalitis relapse. Brain Dev 15:178–181CrossRefPubMed

16.

Armangue T, Moris G, Cantarín-Extremera V et al (2015) Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology 85:1736–1743CrossRefPubMedPubMedCentral

17.

Armangue T, Leypoldt F, Málaga I et al (2014) Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 75:317–323CrossRefPubMedPubMedCentral

18.

Hacohen Y, Deiva K, Pettingill P et al (2014) N‑methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 29:90–96CrossRefPubMed

19.

Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J (2011) Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 77:589–593CrossRefPubMedPubMedCentral

20.

Camdessanché J‑P, Streichenberger N, Cavillon G et al (2011) Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. Eur J Neurol 18:929–931CrossRefPubMed

21.

Blanke ML, VanDongen AMJ (2009) Activation Mechanisms of the NMDA Receptor. In: Van Dongen AM (Hrsg) Biology of the NMDA Receptor. CRC Press Taylor & Francis, Boca Raton FL

22.

Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol (oxford) 29:97–115CrossRef

23.

Joubert B, Honnorat J (2015) Autoimmune channelopathies in paraneoplastic neurological syndromes. Biochim Biophys Acta 1848:2665–2676CrossRefPubMed

24.

Dalmau J, Gleichman AJ, Hughes EG et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098CrossRefPubMedPubMedCentral

25.

Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR (2012) Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 32:11082–11094CrossRefPubMedPubMedCentral

26.

Mikasova L, De Rossi P, Bouchet D et al (2012) Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 135:1606–1621CrossRefPubMed

27.

Hughes EG, Peng X, Gleichman AJ et al (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30:5866–5875CrossRefPubMedPubMedCentral

28.

Kreye J, Wenke NK, Chayka M et al (2016) Human cerebrospinal fluid monoclonal N‑methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain. https://doi.org/10.1093/brain/aww208

29.

Planagumà J, Leypoldt F, Mannara F et al (2015) Human N‑methyl D‑aspartate receptor antibodies alter memory and behaviour in mice. Brain 138:94–109CrossRefPubMed

30.

Kayser MS, Dalmau J (2016) Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res 176:36–40CrossRefPubMed

31.

Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523–533CrossRefPubMed

32.

Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365–384CrossRefPubMed

33.

Schmitt A, Malchow B, Keeser D, Falkai P, Hasan A (2015) Neurobiologie der Schizophrenie. Nervenarzt 86:324–331CrossRefPubMed

34.

Deakin J, Lennox BR, Zandi MS (2014) Antibodies to the N‑methyl-D-aspartate receptor and other synaptic proteins in psychosis. Biol Psychiatry 75:284–291CrossRefPubMed

35.

Ezeoke A, Mellor A, Buckley P, Miller B (2013) A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res 150:245–251CrossRefPubMed

36.

Zandi MS, Irani SR, Lang B et al (2011) Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 258:686–688CrossRefPubMed

37.

Steiner J, Walter M, Glanz W et al (2013) Increased prevalence of diverse N‑methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N‑methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 70:271–278CrossRefPubMed

38.

Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS (2014) Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med 44:2475–2487CrossRefPubMed

39.

Dahm L, Ott C, Steiner J et al (2014) Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 76:82–94CrossRefPubMed

40.

Busse S, Busse M, Brix B et al (2014) Seroprevalence of N‑methyl-D-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients. Eur Arch Psychiatry Clin Neurosci 264:545–550CrossRefPubMed

41.

Gresa-Arribas N, Titulaer MJ, Torrents A et al (2014) Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 13:167–177CrossRefPubMed

42.

Castillo-Gómez E, Oliveira B, Tapken D et al (2016) All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. Mol Psychiatry. https://doi.org/10.1038/mp.2016.125 PubMed

43.

Lennox BR, Palmer-Cooper EC, Pollak T et al (2017) Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry 4:42–48CrossRefPubMed

44.

Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J (2010) In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis 5:31CrossRefPubMedPubMedCentral

45.

Bien CG, Vincent A, Barnett MH et al (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622:1638

46.

Graus F, Titulaer MJ, Balu R et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404CrossRefPubMedPubMedCentral

47.

Veciana M, Becerra JL, Fossas P et al (2015) EEG extreme delta brush: An ictal pattern in patients with anti-NMDA receptor encephalitis. Epilepsy Behav 49:280–285CrossRefPubMed

48.

Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79:1094–1100CrossRefPubMedPubMedCentral

49.

Clancy RR, Bergqvist AGC, Dlugos DJ (2003) Neonatal Electroencephalography. Current Practice of Clinical Electroencephalography. Lippincott Williams &Wilkins, Philadelphia Baltimore, S 160–234

50.

Chanson E, Bicilli É, Lauxerois M et al (2016) Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus? Neurophysiol Clin 46:17–25CrossRefPubMed

51.

Iizuka T, Yoshii S, Kan S et al (2010) Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol 257:1686–1691CrossRefPubMedPubMedCentral

52.

Llorens V, Gabilondo I, Gómez-Esteban JC et al (2010) Abnormal multifocal cerebral blood flow on Tc-99m HMPAO SPECT in a patient with anti-NMDA-receptor encephalitis. J Neurol 257:1568–1569CrossRefPubMed

53.

Prüss H, Finke C, Höltje M et al (2012) N‑methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 72:902–911CrossRefPubMedPubMedCentral

54.

Dogan Onugoren M, Golombeck KS, Bien C et al (2016) Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm 3:e207CrossRefPubMedPubMedCentral

55.

van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607CrossRefPubMed

56.

Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I (2016) Bortezomib treatment for patients with anti-N-methyl-d-Aspartate receptor encephalitis. JAMA Neurol 73:1251–1253CrossRefPubMed

57.

Scheibe F, Prüss H, Mengel AM et al (2017) Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 88:366–370CrossRefPubMed

58.

Lee W‑J, Lee S‑T, Moon J et al (2016) Tocilizumab in autoimmune encephalitis refractory to Rituximab: an institutional cohort study. Neurotherapeutics 13:824–832CrossRefPubMedPubMedCentral

Titel: Update Anti-N-Methyl-D-Aspartat-Rezeptor-Enzephalitis
verfasst von: S. Kovac
J. Alferink
D. Ahmetspahic
V. Arolt
PD Dr. N. Melzer
Publikationsdatum: 20.09.2017
Verlag: Springer Medizin
Schlagwörter: Enzephalitis
Autoimmunenzephalitis
Schizophrenie
Erschienen in: Der Nervenarzt / Ausgabe 1/2018
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-017-0405-0

Neu in den Fachgebieten Neurologie und Psychiatrie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Update Anti-N-Methyl-D-Aspartat-Rezeptor-Enzephalitis

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Manche Gestagene können das Risiko für Meningeome erhöhen

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Perinatale PTBS: Signifikanter Anstieg der Diagnoserate

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Kann die Online-Therapie die Psychotherapie sinnvoll ergänzen? Pro

Wahn: aktuelle psychodynamische und neurokognitive Ansätze

Die ambulante Betreuung von Patienten mit somatisch nicht erklärten Beschwerden

Opfer Therapeut: Wenn Psychiater und Psychotherapeuten gestalkt werden

Psychosoziale Versorgung von Flüchtlingen in Deutschland

Zur Rolle der Psychopharmakotherapie in der Entwicklung der Sozialpsychiatrie

Neu in den Fachgebieten Neurologie und Psychiatrie

Manche Gestagene können das Risiko für Meningeome erhöhen

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Perinatale PTBS: Signifikanter Anstieg der Diagnoserate

Wie toxische Männlichkeit der Gesundheit von Männern schadet